New drug targets Hard-to-Treat cancers with specific gene change
Disease control
Not yet recruiting
This early study tests a new drug called 3HP-2827 in adults with advanced solid tumors that have a specific genetic change (FGFR2 alteration). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 130 participants will take part in two …
Phase: PHASE1 • Sponsor: 3H (Suzhou) Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC